Nature’s Blueprint
ONE
Microorganisms regulate health and disease.
We now have the capability to interrogate these processes, both ‘the good’ and ‘the bad,’ at a pathway and molecular level.
TWO
We have built the technology to mine the genomes of living organisms.
Data science and differential analysis to uncover novel compounds from nature.
Synthetic biology with contextual and functional high-throughput screening turns these discoveries into products across broad applications.
THREE
The 4Sight discovery platform is a disease agnostic approach to identify novel peptides and metabolites from the microbial world.
FOUR
Genevive is at the forefront of the genome mining in biotech.
FIVE
The 4Sight discovery platform is a disease agnostic approach to identify novel peptides and metabolites from the microbial world.
LEADERSHIP
Leadership
Genevive is backed by deep experience in biotech and IBD.
Leadership
Board
- Shann Yu, PhD
Abbvie Ventures - Jose Carlos Gutierrez-Ramos, PhD Chief Science Officer
Danaher Repertoire Immune Medicines, Synlogic, Abbvie, Pfizer, GSK, Harvard
SAB/Clinical
- Silvio Danese, MD PhD
Professor and Head of Gastroenterology, Humanitas, Milan Italy
Past president European Crohn’s and Colitis Organization - Balfour Sartor, MD PhD
Professor of Medicine (GI)
Co-Director UNC Multidisciplinary IBD Center